Background: gastric cancer patients are first diagnosed with an unresectable tumor in up to 40% of cases. Gastric outlet obstruction causes nausea, vomiting, dehydration and malnutrition. The aim of the study was to compare self-expanding metal stents to antrectomy and Roux-en Y gastrojejunostomy for palliation of obstructive adenocarcinoma of the gastric antrum.
INTRODUCTION
Gastric cancer patients present with an unresectable tumor in up to 40% of cases (1, 2) . Gastric outlet obstruction (GOO) is a frequent complications and presents as nausea, vomiting, dehydration and eventually malnutrition. Most patients at this stage have a short life expectancy if left without treatment (3) (4) (5) . Open gastrojejunostomy (OGJ) has been considered the preferred treatment for relieving malignant GOO with good results and adequate symptom relief in most cases. Early major complications of OGJ can be seen in 6% of patients and late complications in up to 17%, and are similar to those of self-expanding metal stents (SEMS) (6% for early and 18% for late complications) (6) . However, OGJ has a higher overall mortality when compared to SEMS (29 vs. 17%; p < 0.001) (7) .
Patients with OGJ have delayed gastric emptying, which can decrease oral intake for up to 8 days (8) . While laparoscopic gastrojejunostomy is less invasive, adequate gastrointestinal function can also be delayed for a similar period, with this approach (9) . Gastric stents are less invasive than surgery, allow for shorter hospital stays and earlier oral intake (10) . There are a number of studies that compare palliative endoscopy with surgical treatment; however, most of them include patients with malignant GOO secondary to a variety of malignancies, including gastric, duodenal and biliopancreatic tumors. The aim of the present study was to compare SEMS with antrectomy and Roux-en Y gastrojejunostomy (A-RYGJ) for palliation of obstructive adenocarcinoma of the gastric antrum.
METHODS
Retrospective, comparative study of a series of consecutive cases with malignant GOO secondary to gastric adenocarcinoma between January 2005 and December 2010 treated at the Instituto Nacional de Cancerologia in Mexico City. Patients over 18 years of age with stage IV tumors (any T, any N, Metastasis) candidates for palliative surgical or endoscopic treatment who were followed-up until death, were included. Patients with GOO secondary to causes other than gastric cancer (duodenal, pancreatic, ampullary, gallbladder cancer or extrahepatic cholangiocarcinoma) and those who were lost to follow up were excluded. Patients were divided into two groups: group A received endoscopic placement of a SEMS if there was GOO with metastatic disease and group B underwent A-RYGJ. A-RYGJ was considered when patients had metastatic diseases and was impossible to place a SEMS. Collected data included: age, gender, histopathology, clinical stage (TNM classification), performance status (Karnofsky's score), in-hospital stay in days, re-intervention rate, complications, and survival. The technical and clinical success of both endoscopic and surgical procedures was recorded, as well as treatment failures. All placed SEMS were uncovered TTS wallstents (22 mm in diameter and 9 cm in length) manufactured by Boston Scientific.
Definitions
Technical success: adequate position and deployment of the SEMS or performance of A-YRGJ with adequate patency (6) . Clinical success: symptom relief with adequate oral intake (6) . Complications: any adverse event related to treatment. Early complications: those that presented in the first 7 days after treatment (6) . Late complications: those that presented after 7 days of treatment (6). Karnofsky's score: as described (11) . Reintervention: any surgical or endoscopic treatment performed after the initial treatment with the objective of relieving persistent or recurrent symptoms. Survival: time elapsed between initial endoscopic or surgical treatment and death of the patient. Treatment failure: inability to maintain adequate oral intake or symptom relief.
Statistical analysis
Descriptive statistics were used. Nominal variables were analyzed using chi square or Fisher's exact test; for quantitative variables, the Student's t-test with a 95% confidence interval and a significance level of 0.05 was used. Survival was compared with Kaplan-Meier curves.
RESULTS
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patients. The main symptom was abdominal pain (48%); vomiting was present in 37% and postprandial fullness in 15%. The median time to diagnosis was 5.1 months (range: 3.26-6.93). Technical and clinical success was achieved in 100% of cases. On average, oral intake was started within the first day (range: 0.786-1.21 days) from stent deployment. There were three complications (15%) after stent placement, two of them presented early: one patient with abdominal pain and one with distal stent migration treated by stent replacement within 24 hours of initial procedure. The third patient had stent occlusion at follow-up due to tumor in-growth and was treated with argon plasma coagulation. Overall survival for this group was 3.7 months. The mean in-hospital stay was 0.94 days (range: 0.16-3.56) per patient, nine patients (47%) were hospitalized overnight for observation, seven (37%) were discharged home after the procedure, and three (16%) required a hospital stay of more than one day. Group B included eight male and 12 female patients with a median age of 55.4 years (range: 48.8-62) and a median Karnofsky's score of 80 (range: 70-90), the TNM clinical stage was also IV for all patients. The main symptoms for this group were abdominal pain (45%), vomiting (30%) and postprandial fullness (25%). The median time to diagnosis was 4.2 months (range: 2.33-6.09). A-YRGJ was technically successful in 100% of the cases with a 95% clinical success rate. Oral intake was started after a median of 4.9 days (range: 4.69-5.1). There were complications in 30% of the cases, 10% were early (2 cases of pneumonia) and 20% were late (1 case of benign postsurgical stenosis of the gastrojejunostomy that presented 4 months after surgery, and 3 cases of obstruction for tumor recurrence at the anastomosis). The patient with stenosis of the gastrojejunostomy was managed by SEMS placement. The other three patients with cancer recurrence were treated by nasogastric tube to decompress the remnant stomach because of the short expected survival. The median survival in this group was 4.5 months (range 3.1-5.8) and the median in-hospital stay was 7.8 days (5.25-10.35).
There were no statistically significant differences between groups with regards to age, BMI, Karnofsky's score, hemoglobin level, albumin, duration of symptoms prior to treatment or survival. The technical and clinical success was similar for both groups (Table II) . However, there was a statistically significant difference between groups favoring SEMS in time to oral intake (1 ± 0 vs. 4.9 ± 0.6 days, p = 0.0001) and hospital stay (0.94 ± 1.18 vs. 7.8 ± 7.7 days, p = 0.0005). We did not find statistically significant differences between surgical and endoscopic treatment with regards to long-term survival (Table II, Fig. 1 ).
DISCUSSION
Several factors must be considered before deciding to perform either a surgical or endoscopic treatment for palliation of GOO. Most clinical trials do not distinguish between different causes of GOO (pancreatic, duodenal or gastric cancer), which is important when comparing endpoints, as highlighted in a study by Kim et al. (12) . In this study, the authors reported a statistically significant difference in survival (153 vs. 90 days, p = 0.041) after placement of a SEMS (partially covered Hercules SP stent, S&G Biotech) in 207 patients with malignant GOO (147 due to gastric and 60 due to pancreatic cancer); survival was greater in patients with gastric cancer patients owing to a less aggressive biological behavior in comparison with pancreatic cancer.
The main objective of palliation in malignant gastric outlet obstruction is symptom control and restoration of oral intake. The choice of treatment depends on the expected survival for each patient.
When the expected survival is only a few days, the best choice is the placement of a nasojejunal feeding tube, while a gastrojejunostomy has been the standard of treatment for patients with a longer life expectancy.
When laparoscopic gastrojejunostomy and OGJ were compared, the results in terms of bleeding (p = 0.0001), shorter interval to oral intake (p = 0.04) and shorter inhospital stay, favored laparoscopic gastrojejunostomy (13) . However, when SEMS were compared with either laparoscopic or OGJ; the results in terms of time to oral intake (1-2.4 vs. 4-9 days) (6, (14) (15) (16) (17) , in-hospital stay (2-7.1 vs. 10-11.5 days) (6, (15) (16) (17) (18) and shorter procedure time (16) were statistically better for SEMS. As to morbidity and mortality many studies have reported that SEMS have more early complications (p = 0.004), shorter time to recurrence of obstructive symptoms (p = 0.002), and to re-intervention (p = 0.004) (16, 18) . Also stents have proved to be less expensive than surgery (15, 19, 20) ; have lower 30 day mortality (16.6 vs. 29.4%) and complication rate (4 vs. 17.6%) and similar overall survival rate (15-20 vs. 21.6-23 weeks) (6,17) without statistically significant difference (20) . It has also been reported that 83% of patients with SEMS alive after 30 days are able to eat solid foods (20) . In the present study, the frequency of complications was lower for endoscopic treatment (15 vs. 30%). Recurrent symptoms that require re-intervention have been reported in 13 to 18% of SEMS vs. 1% of OGJ (6, 21) . Longer survival and probability of prostheses occlusion (tumor in-growth or overgrowth ) or gastrojejunostomy occlusion due to tumor recurrence at the anastomotic site, are directly related. Derivative surgical procedures carry a greater chance of occlusion due to tumor growth towards gastrojejunostomy site. However in our patients the re-intervention rate was higher in the surgical group, probably because of tumoral recurrence secondary to the advanced stage of the disease. It should also be considered that some patients will have persistent obstructive symptoms even after SEMS placement (8%) or OGJ (9%), which reflects the advanced stage in which they present (mesenteric involvement and carcinomatosis) (6) . This can explain the similar rates of long-term obstruction in patients treated with SEMS and gastrojejunostomy. It is clear that in patients with stage IV gastric cancer, the benefits of endoscopic or surgical treatment are similar. However, surgery posses a greater risk for complications, longer in-hospital stay and longer time to oral intake after the procedure. Although the disadvantages of our study are that this it is retrospective, non-randomized and not directly comparative to laparoscopic techniques, as well as the lack of data about the presence of pain or quality of life; it has the advantages of including patients in both groups with similar age, duration of symptoms, same etiology and clinical stage. Also we did not compare SEMS with A-RYGJ. Finally, we have to admit that we still need clinical trials including other types of SEMS and laparoscopic techniques.
CONCLUSION
In patients with malignant GOO due to gastric cancer, endoscopic palliation with SEMS can provide a shorter interval to oral intake, shorter in hospital stay and lower rate of complications compared to A-RYGJ, with similar overall survival rate.
